Dr. William Williams reports

BRIACELL THERAPEUTICS CORP. ANNOUNCES RESULTS OF SHAREHOLDER MEETING

Briacell Therapeutics Corp. has released the results of its annual general meeting of shareholders of the company for the year ended July 31, 2024, held on Feb. 5, 2025. A total of 36.26 per cent of the company's issued and outstanding common shares were voted at the meeting.

At the meeting, the shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of the reappointment of MNP LLP as the auditor of the company for the ensuing year and authorizing the directors to fix its remuneration, and the election of each of Dr. William V. Williams, Jamieson Bondarenko, Dr. Jane A. Gross, Dr. Rebecca Taub, Vaughn C. Embro-Pantalony and Martin E. Schmieg as directors of the company.

Detailed results of the votes in connection with the election of the directors are set out in the attached table.

The formal report on voting results with respect to all matters voted upon during the Meeting will be filed on the Company's SEDAR+ profile at www.sedarplus.ca.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.